Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
François Prince(Hôpital du Sacré-Cœur de Montréal), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Nico Wulffraat(Utrecht University), R. ten Cate(Leiden University), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Esther P A H Hoppenreijs(Radboud University Nijmegen), Wineke Armbrust, Marion A. J. van Rossum(Reade), M van Santen-Hoeufft(Maastricht University Medical Centre), Marinka Twilt(University of Calgary)
Cited by 220
Related Papers
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome
|Nature Genetics|2000|951
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
|The Lancet Child & Adolescent Health|2019|214
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155